GLP1r agonist and SGLT-2 inhibitor combination therapy

The small molecule GLP-1 RA, AZD5004, addresses the limitations of current GLP-1 RAs by offering oral administration and combination therapy with SGLT2 inhibitors, ensuring effective glucose control and reduced side-effects through once-daily dosing without up-titration.

WO2026093542A1PCT designated stage Publication Date: 2026-05-07ASTRAZENECA AB
4 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
ASTRAZENECA AB
Filing Date
2025-10-31
Publication Date
2026-05-07
Patent Text Reader

Abstract

The specification relates to the co- administration of small molecule, once-daily, oral glucagon-like peptide-1 receptor agonists and SGLT-2 inhibitors.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Substituted imidazoles as GLP-1 receptor agonists

    US11584751B1

  • C-ARYL glucoside SGLT2 inhibitors and method

    WO2003099836A1

  • Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds and methods of using same

    WO2022017338A1

  • Dosage regime of orforglipron for treating a subject with type 2 diabetes (T2D), obesity, or overweight with at least one weight related comorbidity

    WO2024129676A1